We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+46.89%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.67B
AUM Growth
+$351M
(+27%)
Cap. Flow
+$70.1M
Cap. Flow
% of AUM
4.19%
Top 10 Holdings %
Top 10 Hldgs %
34.79%
Holding
547
New
45
Increased
181
Reduced
257
Closed
36
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$11.8M |
| 2 |
NVIDIA
NVDA
|
+$8.71M |
| 3 |
Apple
AAPL
|
+$8.26M |
| 4 |
SNDK
Sandisk
SNDK
|
+$7.29M |
| 5 |
Marvell Technology
MRVL
|
+$5.44M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Gold Trust
IAU
|
+$8.15M |
| 2 |
SPDR Gold Trust
GLD
|
+$7.23M |
| 3 |
SPDR Gold MiniShares Trust
GLDM
|
+$6.88M |
| 4 |
AstraZeneca
AZN
|
+$5.05M |
| 5 |
British American Tobacco
BTI
|
+$2.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 47.74% |
| 2 | Healthcare | 19.17% |
| 3 | Communication Services | 9.91% |
| 4 | Consumer Discretionary | 7.67% |
| 5 | Consumer Staples | 3.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Rocket Pharmaceuticals
RCKT
$355M
| $59.4K | ﹤0.01% |
17,378
-1,888
| -10% | -$6.28K |
|
452
Atea Pharmaceuticals
AVIR
$386M
| $59.2K | ﹤0.01% |
12,736
-1,128
| -8% | -$5.61K |
|
453
Vanda Pharmaceuticals
VNDA
$314M
| $58.6K | ﹤0.01% |
9,571
-918
| -9% | -$6K |
|
454
Lexeo Therapeutics
LXEO
$351M
| $58.2K | ﹤0.01% |
12,497
-455
| -4% | -$2.46K |
|
455
OmniAb
OABI
$294M
| $56.8K | ﹤0.01% |
23,072
-2,474
| -10% | -$4.91K |
|
|
UXIN
456
Uxin Ltd
UXIN
$354M
| $54.3K | ﹤0.01% |
35,000
| – | – |
|
457
Tenax Therapeutics
TENX
$429M
| $52.4K | ﹤0.01% |
+3,600
| New | +$46K |
|
458
Lyell Immunopharma
LYEL
$318M
| $52.2K | ﹤0.01% |
3,714
-56
| -1% | -$1.01K |
|
459
Avita Medical
RCEL
$146M
| $51.6K | ﹤0.01% |
12,500
+2,500
| +25% | +$10.8K |
|
|
AUTL
460
Autolus Therapeutics
AUTL
$389M
| $51.1K | ﹤0.01% |
31,925
-3,672
| -10% | -$5.76K |
|
461
Larimar Therapeutics
LRMR
$398M
| $50.4K | ﹤0.01% |
16,533
-2,737
| -14% | -$10.9K |
|
462
Neumora Therapeutics
NMRA
$308M
| $50.1K | ﹤0.01% |
29,488
-163
| -0.5% | -$310 |
|
463
Alpha Teknova
TKNO
$260M
| $48.5K | ﹤0.01% |
8,533
-966
| -10% | -$3.84K |
|
464
Foghorn Therapeutics
FHTX
$305M
| $45.6K | ﹤0.01% |
9,344
-1,052
| -10% | -$4.67K |
|
|
PBLS
465
Parabilis Medicines Inc
PBLS
$3.89B
| $43.8K | ﹤0.01% |
+1,600
| New | +$44.2K |
|
|
BOLD
466
Boundless Bio
BOLD
$55.7M
| $42.3K | ﹤0.01% |
+16,900
| New | +$26K |
|
|
DRUG
467
Bright Minds Biosciences
DRUG
$706M
| $42.1K | ﹤0.01% |
600
+100
| +20% | +$7.85K |
|
468
SIGA Technologies
SIGA
$222M
| $41.6K | ﹤0.01% |
11,415
-1,293
| -10% | -$5.79K |
|
469
Orchestra BioMed
OBIO
$229M
| $41.1K | ﹤0.01% |
9,530
-490
| -5% | -$2K |
|
470
Royal Caribbean
RCL
$81.8B
| $40K | ﹤0.01% |
+126
| New | +$35.2K |
|
|
HELP
471
Cybin Inc
HELP
$477M
| $39.7K | ﹤0.01% |
6,000
-400
| -6% | -$2K |
|
472
Fulcrum Therapeutics
FULC
$249M
| $38.8K | ﹤0.01% |
10,605
-1,214
| -10% | -$7.38K |
|
473
AC Immune
ACIU
$234M
| $38.5K | ﹤0.01% |
16,197
-1,655
| -9% | -$4.56K |
|
474
Capricor Therapeutics
CAPR
$405M
| $38.5K | ﹤0.01% |
+1,600
| New | +$48.5K |
|
475
Anavex Life Sciences
AVXL
$232M
| $38.2K | ﹤0.01% |
14,749
-1,696
| -10% | -$5.02K |
|
Similar funds
HA
TFS
GC
PA
JPM
NRI
CPO
LCI
China Universal Asset Management Company's Q2 2026 Portfolio in Review
As of Q2 2026, China Universal Asset Management Company held 547 positions worth $1.67B, up 27% from $1.32B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
China Universal Asset Management Company deployed $70.1M of net new capital in Q2 2026, opening 45 new positions and adding to 181 existing holdings. Its largest new stake was Onto Innovation: 10,200 shares worth $3.86M.
By sector, the portfolio is most concentrated in Technology at 48% of assets, up from 35% a quarter earlier, followed by Healthcare and Communication Services.
On the sell side, the largest reduction was iShares Gold Trust, an estimated $8.15M trimmed.
- China Universal Asset Management Company's largest Q2 2026 buy was Onto Innovation: 10,200 shares worth $3.86M.
- China Universal Asset Management Company added most to Amazon in Q2 2026, an estimated $11.8M increase.
- China Universal Asset Management Company's biggest Q2 2026 reduction was iShares Gold Trust, cutting an estimated $8.15M.
- China Universal Asset Management Company fully exited AstraZeneca in Q2 2026, selling an estimated $5.05M.
- China Universal Asset Management Company's ten largest holdings make up 35% of its $1.67B portfolio in Q2 2026.
- China Universal Asset Management Company opened 45 new positions and closed 36 in Q2 2026.
- China Universal Asset Management Company's portfolio value rose 27% quarter-over-quarter to $1.67B.
Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.